The P2 hAMSCs in the logarithmic growth phase were inoculated into 6-well plates at a dose of 2×105 cells/well. The cells were divided into 4 experimental groups: The NC group; the positive drug group (PG); anti-CD44 antibody (cat. no. A3D8; GeneTex, Inc.) inhibition group NC + A3D8; and PG + A3D8. After 24 h of inoculation, the anti-CD44 antibody (2 µg/ml) was used to inhibit the expression of CD44 molecules in hAMSCs in the incubator at 37°C for 3 or 7 days. The medium was replaced with fresh medium after every 3 days. The expression of CD44 and chondrocyte-associated markers was detected on day 7.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.